Terry is Managing Partner of the firm's Exton office and a partner in the Corporate Department who advises startup, growth-stage and established companies across a range of industries.

Terry believes in building long-term relationships with his clients and takes the time to learn the nuances of their businesses. Clients typically view Terry as their outside general counsel, helping them solve their legal challenges and drive their businesses forward.

Terry advises his clients from formation to exit, including choice of entity, corporate governance, corporate finance, private equity and venture capital transactions, commercial contract preparation and review, employment issues, buy-sell agreements and shareholder disputes, and intellectual property protection and transfer.

For clients engaging in mergers and acquisitions, financing and other significant transactions, Terry takes a hands-on approach in all facets of the applicable transaction, quarterbacking an efficient deal team and tapping the firm’s broad range of subject matter expertise.

Terry is a member of the firm's Mergers & Acquisitions Practice Group, Emerging Companies & Venture Capital Practice Group, Technology Practice Group, and the Family Offices Practice Group.

Representative Matters

Recent engagements in Terry’s mergers and acquisitions practice include representation of:

• Shareholders of a consumer products company in their $450 million sale of the company's capital stock.
• Management of a telecommunications infrastructure company in a $400 million management buy-out.
• A chemistry research organization in its $110M acquisition transaction.
• A telecommunications company in its $90 million acquisition of towers and related contracts.
• A publicly held pharmaceutical company in its $42 million acquisition of all of the capital stock of a privately held pharmaceutical company.
• An occupational health company in its $35 million sale to a national physical therapy company.
• A private practice in the specialty field of intraoperative neuromonitoring in connection with the sale by its shareholders of all of the capital stock of the company for $34 million.
• A food packager/distributor in a $27 million sale of its assets, including its real estate.
• A privately held pharmaceutical solutions software company in connection with the sale by its shareholders of all of the capital stock of the company for $21 million.

Recent engagements in Terry’s mergers and acquisitions practice include representation of:

• An international private equity fund in over $1 billion of private investment transactions, ranging in size from $2 million to $200 million per investment.
• A life sciences technology and services company in its $150M preferred equity financing and recapitalization transaction.
• A telehealth company in its $80M preferred equity financing and recapitalization transaction.
• A venture capital fund in its $8 million and $12 million Preferred Stock investments in medical device companies.
• A medical device company in its $3 million sale of Series Seed Preferred Stock, $11 million sale of Series A Preferred Stock, and $18 million sale of Series D Preferred Stock.
• A software company in its $15 million sale of Series B Preferred Stock.
• A startup pharmaceutical company in its formation, financing, and $10 million purchase of drug compound and related intellectual property from an international pharmaceutical company.